Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Critical Care
Volume 2015 (2015), Article ID 143832, 4 pages
http://dx.doi.org/10.1155/2015/143832
Case Report

Ciprofloxacin-Induced Thrombotic Thrombocytopenic Purpura: A Case of Successful Treatment and Review of the Literature

1Division of Pulmonary and Critical Care Medicine, Bronx Lebanon Hospital Center, Bronx, NY 10457, USA
2Department of Internal Medicine, Bronx Lebanon Hospital Center, Albert Einstein College of Medicine, Bronx, NY 10457, USA

Received 2 September 2015; Revised 12 October 2015; Accepted 13 October 2015

Academic Editor: Caterina Mammina

Copyright © 2015 Hafiz Rizwan Talib Hashmi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. H. Deck and L. G. Winston, “Sulfonamides, trimethoprim, & quinolones,” in Basic & Clinical Pharmacology, B. G. Katzung and A. J. Trevor, Eds., McGraw-Hill Education, New York, NY, USA, 13th edition, 2015. View at Google Scholar
  2. J. Bertino Jr. and D. Fish, “The safety profile of the fluoroquinolones,” Clinical Therapeutics, vol. 22, no. 7, pp. 798–817, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. S. P. Surana, Z. Sardinas, and A. S. Multz, “Moxifloxacin (Avelox) induced thrombotic thrombocytopenic purpura,” Case Reports in Medicine, vol. 2012, Article ID 459140, 3 pages, 2012. View at Publisher · View at Google Scholar
  4. J. L. Moake, “Thrombotic microangiopathies,” The New England Journal of Medicine, vol. 347, no. 8, pp. 589–600, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. D. R. Terrell, L. A. Williams, S. K. Vesely, B. Lämmle, J. A. K. Hovinga, and J. N. George, “The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency,” Journal of Thrombosis and Haemostasis, vol. 3, no. 7, pp. 1432–1436, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. G. A. Rock, K. H. Shumak, N. A. Buskard et al., “Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura,” The New England Journal of Medicine, vol. 325, no. 6, pp. 393–397, 1991. View at Publisher · View at Google Scholar
  7. J. N. George, “Clinical practice. Thrombotic thrombocytopenic purpura,” The New England Journal of Medicine, vol. 354, no. 18, pp. 1927–1935, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. W. F. Clark, A. X. Garg, P. G. Blake, G. A. Rock, A. P. Heidenheim, and D. L. Sackett, “Effect of awareness of a randomized controlled trial on use of experimental therapy,” The Journal of the American Medical Association, vol. 290, no. 10, pp. 1351–1355, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Bapani, N. Epperla, Y. Kasirye, R. Mercier, and R. Garcia-Montilla, “ADAMTS13 deficiency and thrombotic thrombocytopenic purpura associated with trimethoprim-sulfamethoxazole,” Clinical Medicine and Research, vol. 11, no. 2, pp. 86–90, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. E. L. Amorosi and J. E. Ultmann, “Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature,” Medicine, vol. 45, no. 2, pp. 139–159, 1966. View at Publisher · View at Google Scholar
  11. T. J. Torok, R. C. Holman, and T. L. Chorba, “Increasing mortality from thrombotic thrombocytopenic purpura in the United States—analysis of national mortality data, 1968–1991,” American Journal of Hematology, vol. 50, no. 2, pp. 84–90, 1995. View at Publisher · View at Google Scholar · View at Scopus
  12. H.-M. Tsai, “Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion,” Blood, vol. 87, no. 10, pp. 4235–4244, 1996. View at Google Scholar · View at Scopus
  13. J. E. Sadler, J. L. Moake, T. Miyata, and J. N. George, “Recent advances in thrombotic thrombocytopenic purpura,” Hematology/The Education Program of the American Society of Hematology. American Society of Hematology. Education Program, pp. 407–423, 2004. View at Google Scholar · View at Scopus
  14. S. K. Vesely, J. N. George, B. Lämmle et al., “ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients,” Blood, vol. 102, no. 1, pp. 60–68, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. J. W. Smith, R. Weinstein, and K. L. Hillyer, “Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis,” Transfusion, vol. 43, no. 6, pp. 820–822, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Scully, B. J. Hunt, S. Benjamin et al., “Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies,” British Journal of Haematology, vol. 158, no. 3, pp. 323–335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. S. L. Allford, B. J. Hunt, P. Rose, and S. J. Machin, “Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias,” British Journal of Haematology, vol. 120, no. 4, pp. 556–573, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. J. N. George, G. E. Raskob, S. R. Shah et al., “Drug-induced thrombocytopenia: a systematic review of published case reports,” Annals of Internal Medicine, vol. 129, no. 11, pp. 886–890, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Y. Cheah, B. De Keulenaer, and M. F. Leahy, “Fluoroquinolone-induced immune thrombocytopenia: a report and review,” Internal Medicine Journal, vol. 39, no. 9, pp. 619–623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. N. F. Crum and P. Gable, “Quinine-induced hemolytic-uremic syndrome,” Southern Medical Journal, vol. 93, no. 7, pp. 726–728, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. M. D. Blum, D. J. Graham, and C. A. McCloskey, “Temafloxacin syndrome: review of 95 cases,” Clinical Infectious Diseases, vol. 18, no. 6, pp. 946–950, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Cathomas, A. Goldhirsch, and R. von Moos, “Drug-induced immune thrombocytopenia,” The New England Journal of Medicine, vol. 357, no. 18, pp. 1870–1871, 2007. View at Google Scholar
  23. P. J. Medina, J. M. Sipols, and J. N. George, “Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome,” Current Opinion in Hematology, vol. 8, no. 5, pp. 286–293, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Mouraux, M. Gille, F. Piéret, and I. Declercq, “Fulminant thrombotic thrombocytopenic purpura in the course of ciprofloxacin therapy,” Revue Neurologique, vol. 158, no. 11, pp. 1115–1117, 2002. View at Google Scholar · View at Scopus
  25. M. Tuccori, B. Guidi, G. Carulli, C. Blandizzi, M. D. Tacca, and M. Di Paolo, “Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome,” Platelets, vol. 19, no. 5, pp. 384–387, 2008. View at Publisher · View at Google Scholar · View at Scopus